Search

mRNA-1345

mRNA-1345 is a nucleoside modified mRNA encoding the F-glycoprotein from RSV subtype A stabilized in its prefusion conformation.[L53393] It is the primary ingredient of the RSV vaccine mRESVIA. … mRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older.

Cresol

At concentrations normally found in the environment however, cresols do not pose any significant risk for the general population. … Cresol is a hydroxytoluene that can be extracted naturally from coal tar or made synthetically. Pure cresol is a mixture of ortho-, meta-, and para- isomers.

Zilganersen

Zilganersen is a glial fibrillary acidic protein (GFAP)-directed antisense oligonucleotide used to treat Alexander disease. … [L64096] Alexander disease is caused by variants in the *GFAP* gene that lead to overproduction and toxic accumulation of GFAP in astrocytes, and dysfunction in astrocytes can over time damage neurons

Taribavirin

Digitoxin

A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting.

Nitisinone

Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1 and Alkaptonuria. … It is sold under the brand names Orfadin and Harliku. [L53253, L53258]

Efgartigimod alfa

and a reduction in electrical nerve impulses. … [A243759,A243784] Efgartigimod alfa is a first-in-class[L39501] antagonist of the neonatal Fc receptor (FcRn) used in the treatment of MG.

Bamlanivimab

Bamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19. … it in collaboration with Eli Lilly and Company.

Ketoconazole

Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections. … [A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981.

Catumaxomab

Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. … Catumaxumab was approved for market in Canada in May 2012 for the same condition [FDA Label]. It is currently available under the brand name Removab.